Immunodominant antibody germlines in COVID-19.

Andreano, Emanuele; Rappuoli, Rino

Andreano, Emanuele; Rappuoli, Rino.

Andreano E; Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Rappuoli R; Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, Siena, Italy.

J Exp Med ; 218(5)2021 05 03.

Article in English | MEDLINE | ID: covidwho-1114805

ABSTRACT

ABSTRACT

The neutralizing antibody response to SARS-CoV-2 is dominated by antibodies deriving from germlines IGHV3-53/IGHV3-66, which are also associated with self-reacting antibodies. Could vaccines avoid the expansion of this immunodominant response, decrease the risk of autoimmunity, and still protect against emerging SARS-CoV-2 variants?

Subject(s)

Antibodies, Neutralizing/immunology; Antibodies, Viral/immunology; COVID-19/immunology; Germ Cells/immunology; Host-Pathogen Interactions/immunology; SARS-CoV-2/immunology; Antigens, Viral/immunology; COVID-19/genetics; COVID-19/virology; Host-Pathogen Interactions/genetics; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Host-Pathogen Interactions / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Germ Cells / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Jem.20210281

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google